The original guidelines for HER2 testing in breast cancer were jointly published by ASCO and CAP over 10 years ago, updated in 2013, and updated again in 2018.
The Focused Update of the “Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer” clinical practice guideline has been developed by an expert panel of pathologists and oncologists and issued by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) to address new information made available since the guideline’s previous update in 2013.
The 2018 Focused Update addresses uncommon clinical scenarios and improves clarity, particularly for infrequent HER2 test results that are of uncertain biologic or clinical significance. Some of the highlights include:
Published May 30, 2018 as an early online release in Archives of Pathology & Laboratory Medicine.
Sign up to receive updates: